Find Clinical Trials & Studies
Casdatifan and Cabozantinib vs Placebo and Cabozantinib in Patients with ccRCC
I'm Interested!
Please call
1-866-373-1464
1-866-373-1464
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Kidney
Study Purpose
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.
- UH IRB: 25-649;STUDY20251367 / Pro00091046
- StudyID: ARCS1825
- ClinicalTrials.gov: NCT07011719
I'm Interested!
Please call
1-866-373-1464
1-866-373-1464
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL
Cancer Trials: 1-866-373-1464